Mosaic ImmunoEngineering Inc. (CPMV)
USD 0.65
(-22.25%)
USD 0.65
(-22.25%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 5.14 Million USD | 67.7% |
| 2021 | 3.06 Million USD | 248.56% |
| 2020 | 880.34 Thousand USD | 285.76% |
| 2019 | 228.21 Thousand USD | 0.0% |
| 2017 | 84.83 Thousand USD | 49.93% |
| 2016 | 56.58 Thousand USD | -23.02% |
| 2015 | 73.51 Thousand USD | -55.48% |
| 2014 | 165.1 Thousand USD | -43.09% |
| 2013 | 290.14 Thousand USD | 4.47% |
| 2012 | 277.73 Thousand USD | -73.49% |
| 2011 | 1.04 Million USD | 80.98% |
| 2010 | 578.81 Thousand USD | -85.76% |
| 2009 | 4.06 Million USD | -0.3% |
| 2008 | 4.07 Million USD | 102.31% |
| 2007 | 2.01 Million USD | -85.86% |
| 2006 | 14.24 Million USD | 1044.89% |
| 2005 | 1.24 Million USD | -26.37% |
| 2004 | 1.68 Million USD | 117.17% |
| 2003 | 778.04 Thousand USD | -58.55% |
| 2002 | 1.87 Million USD | 36.08% |
| 2001 | 1.37 Million USD | 122.01% |
| 2000 | 621.3 Thousand USD | 18.74% |
| 1999 | 523.26 Thousand USD | -75.39% |
| 1998 | 2.12 Million USD | 105.87% |
| 1997 | 1.03 Million USD | 101.53% |
| 1996 | 512.47 Thousand USD | 75.89% |
| 1995 | 291.36 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 5.86 Million USD | 4.34% |
| 2023 Q1 | 5.42 Million USD | 5.46% |
| 2023 Q2 | 5.62 Million USD | 3.61% |
| 2022 Q3 | 4.79 Million USD | 6.96% |
| 2022 Q4 | 5.14 Million USD | 7.43% |
| 2022 FY | 5.14 Million USD | 67.7% |
| 2022 Q1 | 3.82 Million USD | 24.72% |
| 2022 Q2 | 4.47 Million USD | 17.02% |
| 2021 Q3 | 2.64 Million USD | 25.11% |
| 2021 Q4 | 3.06 Million USD | 15.91% |
| 2021 FY | 3.06 Million USD | 248.56% |
| 2021 Q1 | 1.22 Million USD | 42.93% |
| 2021 Q2 | 2.11 Million USD | 73.07% |
| 2020 Q2 | 182.59 Thousand USD | -40.27% |
| 2020 Q4 | 855.42 Thousand USD | 138.66% |
| 2020 FY | 880.34 Thousand USD | 285.76% |
| 2020 Q1 | 305.67 Thousand USD | -30.77% |
| 2020 Q3 | 358.42 Thousand USD | 96.29% |
| 2019 FY | 228.21 Thousand USD | 0.0% |
| 2019 Q2 | 228.21 Thousand USD | -2.58% |
| 2019 Q3 | 264.89 Thousand USD | 16.07% |
| 2019 Q4 | 441.54 Thousand USD | 66.69% |
| 2019 Q1 | 234.24 Thousand USD | 458.83% |
| 2018 Q2 | 84.83 Thousand USD | -15.73% |
| 2018 Q4 | 41.91 Thousand USD | -46.5% |
| 2018 Q3 | 78.34 Thousand USD | -7.66% |
| 2018 Q1 | 100.68 Thousand USD | 98.3% |
| 2017 Q1 | 58.91 Thousand USD | 12.61% |
| 2017 Q4 | 50.77 Thousand USD | -41.49% |
| 2017 Q2 | 56.58 Thousand USD | -3.95% |
| 2017 Q3 | 86.78 Thousand USD | 53.36% |
| 2017 FY | 84.83 Thousand USD | 49.93% |
| 2016 FY | 56.58 Thousand USD | -23.02% |
| 2016 Q1 | 69.62 Thousand USD | -1.01% |
| 2016 Q4 | 52.31 Thousand USD | -37.09% |
| 2016 Q3 | 83.15 Thousand USD | 13.12% |
| 2016 Q2 | 73.51 Thousand USD | 5.58% |
| 2015 FY | 73.51 Thousand USD | -55.48% |
| 2015 Q1 | 69.19 Thousand USD | -76.22% |
| 2015 Q4 | 70.33 Thousand USD | -21.87% |
| 2015 Q2 | 165.1 Thousand USD | 138.61% |
| 2015 Q3 | 90.02 Thousand USD | -45.47% |
| 2014 FY | 165.1 Thousand USD | -43.09% |
| 2014 Q3 | 229.9 Thousand USD | -20.76% |
| 2014 Q4 | 290.95 Thousand USD | 26.56% |
| 2014 Q1 | 92.35 Thousand USD | -20.2% |
| 2014 Q2 | 290.14 Thousand USD | 214.16% |
| 2013 Q1 | 944.92 Thousand USD | 1120.28% |
| 2013 FY | 290.14 Thousand USD | 4.47% |
| 2013 Q2 | 277.73 Thousand USD | -70.61% |
| 2013 Q4 | 115.73 Thousand USD | 17.54% |
| 2013 Q3 | 98.47 Thousand USD | -64.54% |
| 2012 Q1 | 326.66 Thousand USD | 43.76% |
| 2012 Q3 | 794.58 Thousand USD | -24.15% |
| 2012 FY | 277.73 Thousand USD | -73.49% |
| 2012 Q4 | 77.43 Thousand USD | -90.25% |
| 2012 Q2 | 1.04 Million USD | 220.67% |
| 2011 Q4 | 227.23 Thousand USD | -33.51% |
| 2011 FY | 1.04 Million USD | 80.98% |
| 2011 Q3 | 341.75 Thousand USD | -40.96% |
| 2011 Q2 | 578.81 Thousand USD | 52.47% |
| 2011 Q1 | 379.62 Thousand USD | -72.78% |
| 2010 FY | 578.81 Thousand USD | -85.76% |
| 2010 Q2 | 4.06 Million USD | 6.79% |
| 2010 Q3 | 3.82 Million USD | -5.92% |
| 2010 Q1 | 3.8 Million USD | -6.46% |
| 2010 Q4 | 1.39 Million USD | -63.52% |
| 2009 Q2 | 4.07 Million USD | -24.39% |
| 2009 Q3 | 4.76 Million USD | 16.95% |
| 2009 Q4 | 4.06 Million USD | -14.66% |
| 2009 Q1 | 5.39 Million USD | -15.88% |
| 2009 FY | 4.06 Million USD | -0.3% |
| 2008 Q2 | 2.01 Million USD | -68.24% |
| 2008 FY | 4.07 Million USD | 102.31% |
| 2008 Q1 | 6.34 Million USD | -14.52% |
| 2008 Q4 | 6.4 Million USD | 31.96% |
| 2008 Q3 | 4.85 Million USD | 141.07% |
| 2007 Q3 | 9.3 Million USD | -34.67% |
| 2007 FY | 2.01 Million USD | -85.86% |
| 2007 Q4 | 7.42 Million USD | -20.26% |
| 2007 Q1 | 8.55 Million USD | -22.02% |
| 2007 Q2 | 14.24 Million USD | 66.53% |
| 2006 Q1 | 11.17 Million USD | 562.02% |
| 2006 Q4 | 10.96 Million USD | 171.46% |
| 2006 Q3 | 4.04 Million USD | 224.76% |
| 2006 Q2 | 1.24 Million USD | -88.87% |
| 2006 FY | 14.24 Million USD | 1044.89% |
| 2005 FY | 1.24 Million USD | -26.37% |
| 2005 Q4 | 1.68 Million USD | -4.46% |
| 2005 Q3 | 1.76 Million USD | 4.58% |
| 2005 Q2 | 1.68 Million USD | 35.91% |
| 2005 Q1 | 1.24 Million USD | 44.11% |
| 2004 FY | 1.68 Million USD | 117.17% |
| 2004 Q4 | 862.7 Thousand USD | 5.74% |
| 2004 Q1 | 1.54 Million USD | -14.34% |
| 2004 Q2 | 778.04 Thousand USD | -49.76% |
| 2004 Q3 | 815.88 Thousand USD | 4.86% |
| 2003 Q4 | 1.8 Million USD | -1.76% |
| 2003 Q3 | 1.84 Million USD | -1.96% |
| 2003 Q2 | 1.87 Million USD | -0.74% |
| 2003 Q1 | 1.89 Million USD | 11.64% |
| 2003 FY | 778.04 Thousand USD | -58.55% |
| 2002 FY | 1.87 Million USD | 36.08% |
| 2002 Q3 | 1.12 Million USD | -18.38% |
| 2002 Q1 | 1.31 Million USD | 75.92% |
| 2002 Q2 | 1.37 Million USD | 4.96% |
| 2002 Q4 | 1.69 Million USD | 50.45% |
| 2001 Q4 | 747 Thousand USD | 93.65% |
| 2001 FY | 1.37 Million USD | 122.01% |
| 2001 Q1 | 308.86 Thousand USD | 79.97% |
| 2001 Q2 | 621.3 Thousand USD | 101.16% |
| 2001 Q3 | 385.73 Thousand USD | -37.91% |
| 2000 FY | 621.3 Thousand USD | 18.74% |
| 2000 Q3 | 280.25 Thousand USD | -46.44% |
| 2000 Q2 | 523.26 Thousand USD | -83.73% |
| 2000 Q4 | 171.62 Thousand USD | -38.76% |
| 2000 Q1 | 3.21 Million USD | 9.49% |
| 1999 Q3 | 2.46 Million USD | 0.0% |
| 1999 FY | 523.26 Thousand USD | -75.39% |
| 1999 Q4 | 2.93 Million USD | 19.21% |
| 1998 FY | 2.12 Million USD | 105.87% |
| 1997 FY | 1.03 Million USD | 101.53% |
| 1996 FY | 512.47 Thousand USD | 75.89% |
| 1995 FY | 291.36 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -18658.557% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 45.636% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.899% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -536.26% |
| Rebus Holdings, Inc. | 5.24 Million USD | 1.831% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 91.28% |
| Qrons Inc. | 1.48 Million USD | -245.67% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -319.669% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 93.131% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -11413.413% |
| Skye Bioscience, Inc. | 14.07 Million USD | 63.431% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 90.346% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 46.295% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1120.689% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.716% |
| Intellipharmaceutics International Inc. | 12 Million USD | 57.148% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -33.614% |
| Mesoblast Limited | 188.44 Million USD | 97.269% |
| Marizyme, Inc. | 26.67 Million USD | 80.709% |
| Genus plc | 485 Million USD | 98.939% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 11.922% |
| Pharming Group N.V. | 244.07 Million USD | 97.892% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -156.005% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -104.506% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -35.422% |
| ContraFect Corporation | 32.53 Million USD | 84.181% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -159.729% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -34.444% |
| IMV Inc. | 37.93 Million USD | 86.434% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 56.309% |
| MultiCell Technologies, Inc. | 1617.67 USD | -318014.016% |
| ONE Bio Corp. | 27.49 Million USD | 81.284% |
| Accustem Sciences Inc. | 1.07 Million USD | -376.821% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 93.353% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -143.303% |
| Q BioMed Inc. | 8.13 Million USD | 36.726% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.795% |
| Biomind Labs Inc. | 1.49 Million USD | -243.387% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.665% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 43.089% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 72.038% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -258.894% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3521.545% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2458.74% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 10.439% |
| GB Sciences, Inc. | 5.41 Million USD | 5.012% |
| Alpha Cognition Inc. | 7.16 Million USD | 28.176% |
| HST Global, Inc. | 593.59 Thousand USD | -766.93% |
| CSL Limited | 18.62 Billion USD | 99.972% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -308.677% |
| Halberd Corporation | 728.71 Thousand USD | -606.175% |
| Enzolytics Inc. | 365.26 Million USD | 98.591% |
| Agentix Corp. | 2.51 Million USD | -104.976% |
| Resverlogix Corp. | 67.39 Million USD | 92.364% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -513.549% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.843% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -200.235% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 79.205% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 56.767% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -40.404% |
| AVAX Technologies, Inc. | 3.99 Million USD | -28.852% |
| Zenith Capital Corp. | 27.56 Thousand USD | -18566.02% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.612% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2056.274% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -37.804% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -655.843% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -89.776% |
| Kadimastem Ltd | 3.5 Million USD | -46.825% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -7588.797% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.762% |
| BioStem Technologies, Inc. | 15.9 Million USD | 67.644% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1007.391% |
| LadRx Corporation | 2.2 Million USD | -133.855% |
| Cell Source, Inc. | 15.8 Million USD | 67.444% |
| Regen BioPharma, Inc. | 5.45 Million USD | 5.709% |
| Regen BioPharma, Inc. | 5.45 Million USD | 5.709% |
| NovAccess Global Inc. | 7.86 Million USD | 34.535% |
| Affymax, Inc. | 8.87 Million USD | 41.99% |
| Itoco Inc. | 1.65 Million USD | -211.286% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -150.835% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 14.928% |
| Mobile Lads Corp. | 1.31 Million USD | -291.781% |
| CytoDyn Inc. | 127.89 Million USD | 95.976% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -12211.383% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -228.531% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 53.41% |
| SYBLEU INC | 681.41 Thousand USD | -655.201% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 15.665% |
| International Stem Cell Corporation | 5.27 Million USD | 2.482% |
| Bioxytran, Inc. | 3.24 Million USD | -58.364% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -722.301% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -11.455% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 87.447% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 76.887% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -154.077% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 6.06% |
| Neutra Corp. | 973.52 Thousand USD | -428.596% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 82.264% |
| PureTech Health plc | 125.58 Million USD | 95.902% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -36.967% |
| IXICO plc | 1.9 Million USD | -170.802% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 74.933% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.02% |
| CSL Limited | 18.62 Billion USD | 99.972% |
| Cellectis S.A. | 249.36 Million USD | 97.936% |